Predictors of virological failure and time to viral suppression of first line integrase inhibitor based antiretroviral treatment

HIV / AIDS

First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines: a cohort study

AIDS.

Bouzidi KEL, Jose S, Phillips AN, Pozniak A, Ustianowski A, Gompels M, Winston A, Schaap A, Dunn DT, Sabin CA, UK CHIC Study.

doi: 10.1097/QAD.0000000000002603.

HIV / AIDS

Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure

HIV Med.

Borghetti A, Moschese D, Cingolani A, Baldin G, Speziale D, Ciccullo A, Lombardi F, Emiliozzi A, Belmonti S, Antinori A, Cauda R, Di Giambenedetto S

doi: 10.1111/hiv.12759.

SPECIAL REPORT

HIV / AIDS

11^e Conférence de la Société internationale sur le SIDA (IAS) 2021

HIV / AIDS

Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort

HIV Med

Fabbiani M, Rossetti B, Ciccullo A, Oreni L, Lagi F, Celani L, Colafigli M, De Vito A, Mazzitelli M, Dusina A, Durante M, Montagnani F, Rusconi S, Capetti A, Sterrantino G, D'Ettorre G, Di Giambenedetto S, ODOACRE Study Group.

doi: 10.1111/hiv.13146

HIV / AIDS

Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial

J Acquir Immune Defic Syndr.

Boatman JA, Baker JV, Emery S, Furrer H, Mushatt DM, Sedláček D, Lundgren JD, Neaton JD; INSIGHT START Study Group

doi: 10.1097/QAI.

HIV / AIDS

Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1

N Engl J Med.

NAMSAL ANRS 12313 Study Group.

doi: 10.1056/NEJMoa

HIV / AIDS

Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study

HIV Med.

Mwasakifwa GE, Amin J, White CP, Center JR, Kelleher A, Boyd MA

doi: 10.1111/hiv.12882.

HIV / AIDS

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study

Clin Infect Dis.

van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla J, Routy JP, Wyen C, Ait-Khaled M, Nascimento MC, Pappa KA, Wang R, Wright J, Tenorio AR, Wynne B, Aboud M, Gartland MJ, Smith KY

doi: 10.1093/cid/ciz1243.

HIV / AIDS

Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific

HIV Med

Ross J, Jiamsakul A, Kumarasamy N, Azwa I, Merati TP, Do CD, Lee MP, Ly PS, Yunihastuti E, Nguyen KV, Ditangco R, Ng OT, Choi JY, Oka S, Sohn AH, Law M

doi: 10.1111/hiv.13006

Related content

First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines: a cohort study

Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure

11e Conférence de la Société internationale sur le SIDA (IAS) 2021

Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort

Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial

Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1

Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study

Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific

11^e Conférence de la Société internationale sur le SIDA (IAS) 2021